Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Material Agreement (Mar 6, 2024)

Reports
Material Agreements·Other Events·Exhibits & Filings
Filing Date
Filed March 6, 2024
Period End
March 5, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · May ’23May ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed March 6, 2024. Cited figures are marked; the original filing is the authoritative source.

On March 5, 2024, BridgeBio Pharma, Inc. entered into an Underwriting Agreement with J.P.

Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the underwriters, for an underwritten public offering of 8,620,690 shares of common stock at $29.00a per share. The Company estimates net proceeds of approximately $250.0 million, excluding any exercise of the underwriters' 30-day option to purchase up to an additional 1,293,103 shares. The offering is expected to close on or about March 8, 2024, subject to customary closing conditions, and is being made under an effective Form S-3ASR shelf registration statement.

The Company said it expects to use the net proceeds to fund the commercial launch of acoramidis, if approved, and the clinical and pre-clinical development of its current and future product candidates, research activities, and working capital and general corporate purposes. It may also use a portion of the proceeds to invest in or acquire complementary businesses or technologies, though it stated it has no current plans, commitments or agreements for any such material investments or acquisitions. The Company believes its existing cash and cash equivalents, together with the offering proceeds, will be sufficient to fund operations into the second half of 2026.

The Company and its directors and executive officers agreed not to sell or transfer Common Stock for 60 days after the Prospectus date, subject to certain exceptions and the written consent of J.P. Morgan Securities LLC. The filing also includes the Underwriting Agreement and a legal opinion from Goodwin Procter LLP as exhibits, and two press releases: one announcing the launch of the offering on March 4, 2024 and one announcing its pricing on March 5, 2024.

Key Highlights

  1. Public offering of 8,620,690 shares of common stock priced at $29.00 per share, with the Company as the sole seller of shares.
  2. Estimated net proceeds of approximately $250.0 million, excluding any exercise of the underwriters' option for up to 1,293,103 additional shares.
  3. Underwriters hold a 30-day option to purchase additional shares at the public offering price less underwriting discounts and commissions.
  4. Offering expected to close on or about March 8, 2024, subject to customary closing conditions.
  5. Proceeds earmarked for the potential commercial launch of acoramidis, clinical and pre-clinical development, research, and general corporate purposes.
  6. Company believes existing cash plus offering proceeds will fund operations into the second half of 2026.
  7. Company and its directors and executive officers are subject to a 60-day lock-up on sales or transfers of Common Stock, subject to exceptions and J.P. Morgan's consent.

Frequently Asked Questions

  1. How much capital is BridgeBio raising and at what price?

    The Company is offering 8,620,690 shares of common stock at $29.00 per share, with estimated net proceeds of approximately $250.0 million before any exercise of the underwriters' option for up to 1,293,103 additional shares.

  2. What will the money be used for?

    The Company currently expects to use the net proceeds to fund the commercial launch of acoramidis, if approved, clinical and pre-clinical development of current and future product candidates, research activities, and working capital and other general corporate purposes. It may also use a portion for acquisitions or investments in complementary businesses or technologies, but has no current plans, commitments or agreements for any such material transaction.

  3. How long will the Company's cash last after this offering?

    The Company believes its existing cash and cash equivalents, together with the net proceeds from the offering, will be sufficient to fund its operations into the second half of 2026.

  4. When is the offering expected to close, and what restrictions apply to insiders?

    The offering is expected to close on or about March 8, 2024, subject to customary closing conditions. The Company and its directors and executive officers agreed not to sell or transfer Common Stock for 60 days after the Prospectus date without the written consent of J.P. Morgan Securities LLC, subject to certain exceptions.